Wellington Management Group LLP lifted its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 1.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 742,745 shares of the company's stock after purchasing an additional 8,125 shares during the quarter. Wellington Management Group LLP owned 1.53% of Axsome Therapeutics worth $66,750,000 at the end of the most recent reporting period.
Several other hedge funds have also bought and sold shares of AXSM. Northwestern Mutual Wealth Management Co. bought a new position in shares of Axsome Therapeutics in the second quarter valued at approximately $27,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Axsome Therapeutics in the 2nd quarter valued at $47,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Axsome Therapeutics by 22.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company's stock worth $156,000 after acquiring an additional 318 shares during the last quarter. Moors & Cabot Inc. bought a new stake in shares of Axsome Therapeutics in the 3rd quarter worth $200,000. Finally, Whalen Wealth Management Inc. purchased a new stake in shares of Axsome Therapeutics in the third quarter valued at about $236,000. Institutional investors and hedge funds own 81.49% of the company's stock.
Axsome Therapeutics Stock Performance
Shares of NASDAQ AXSM traded down $1.08 during trading on Wednesday, hitting $97.74. The company had a trading volume of 481,190 shares, compared to its average volume of 610,865. The firm has a market capitalization of $4.74 billion, a P/E ratio of -14.97 and a beta of 1.18. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $105.00. The stock has a 50 day simple moving average of $92.80 and a 200 day simple moving average of $87.08. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 and a current ratio of 2.44.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, topping analysts' consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The firm had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. During the same quarter in the prior year, the company posted ($1.32) earnings per share. As a group, analysts anticipate that Axsome Therapeutics, Inc. will post -4.6 earnings per share for the current year.
Wall Street Analyst Weigh In
Several equities research analysts have commented on the stock. StockNews.com upgraded shares of Axsome Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday, November 20th. Cantor Fitzgerald reissued an "overweight" rating and issued a $107.00 price objective on shares of Axsome Therapeutics in a research report on Monday, September 16th. Royal Bank of Canada raised their target price on Axsome Therapeutics from $130.00 to $131.00 and gave the company an "outperform" rating in a research report on Friday, October 4th. Wells Fargo & Company initiated coverage on shares of Axsome Therapeutics in a report on Tuesday, September 3rd. They issued an "overweight" rating and a $140.00 price target on the stock. Finally, Robert W. Baird raised their price objective on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $124.93.
Get Our Latest Stock Report on AXSM
Axsome Therapeutics Profile
(
Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Further Reading
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
